Inhibition of Skp2 enhances anti-tumor immunity of macrophages by regulating CD47 in gastric cancer
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115262 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Kaizhao Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Laboratory Animal Center, State Key Laboratory of Esophageal Cancer…. Hauptthemen laut MEDLINE: S-Phase Kinase-Associated Proteins, Stomach Neoplasms, CD47 Antigen, Macrophages. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
S-phase kinase-associated protein 2 (Skp2), a member of the ubiquitin E3 ligase F-box family, has been confirmed to control the tumorigenesis and progression of varieties of tumors, and is a potential pharmacological target for anticancer therapy. Recent research reveal that Skp2 affects tumor immune microenvironment through regulating immune checkpoints. However, the effect of Skp2 on the tumor microenvironment (TME) and its underlying regulatory mechanism in gastric cancer is still unclear. This study was aim to investigate the role of Skp2 in gastric cancer immunotherapy. Through database and experimental analysis, it was found that inhibition of Skp2 could reduce the expression of tumor immune checkpoint CD47. Co-culture experiments in vitro showed that inhibition of Skp2 could enhance the phagocytosis of macrophages on gastric cancer cells. Further studies showed that Skp2 affected the expression of the lysosomal protein RAGA and regulated the degradation of CD47 lysosomes. Subsequently, a gastric cancer SNU601 xenograft model also showed that inhibition of Skp2 downregulated CD47 levels in vivo. Small inhibitor of Skp2 combined with 5-FU chemotherapy could synergistically inhibit tumor growth, which affected the changes of immune microenvironment and regulated the infiltration of macrophages. To sum up, this study confirmed that Skp2 as an important regulator of phagocytosis and provided a new theoretical basis for improving anti-tumor immune efficacy and related drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Laboratory Animal Center, State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan Provin…
- Key Laboratory of Technology of Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Pharmaceutical Sciences, Zhengzhou…
- Department of Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer and Zhengzhou Key Laboratory for…
Zitieren
APA
Hu, K., Zhao, L., Miao, P., Qiu, W., Ai, L., Chen, X., Wang, S. Q., Chen, X., & Shi, X. J. (2025). Inhibition of Skp2 enhances anti-tumor immunity of macrophages by regulating CD47 in gastric cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115262
Vancouver
Hu K, Zhao L, Miao P, Qiu W, Ai L, Chen X, et al. Inhibition of Skp2 enhances anti-tumor immunity of macrophages by regulating CD47 in gastric cancer. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115262
BibTeX
@article{Hu2025,
author = {Hu, Kaizhao and Zhao, Lidan and Miao, Peipei and Qiu, Wenhui and Ai, Lu and Chen, Xi and Wang, Sai-Qi and Chen, Xiaobing and Shi, Xiao-Jing},
title = {Inhibition of Skp2 enhances anti-tumor immunity of macrophages by regulating CD47 in gastric cancer},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115262}
}
EUVIMED